Recent advances of precision immunotherapy in sepsis

Abstract

Precision immunotherapy signifies the administration of the required type of immune intervention tailored to the state of immune activation at the appropriate time window. The classification of patients into the different states of immune activation is usually done by either a protein blood biomarker or a molecular blood endotype that is diagnostic of the precise immune state. Evidence coming from trials of the last decade suggests that immune interventions should be split into strategies aiming to attenuate the exaggerated immune responses, restore sepsis-induced immunoparalysis (SII) and restore the vascular tone. Suggested strategies to attenuate the immune responses are anakinra, nangibotide and tocilizumab. Biomarkers that guide their use are ferritin, soluble triggering receptor expressed on myeloid cells-1 and C-reactive protein. Suggested strategies to restore SII are nivolumab, recombinant human interferon-gamma, CYT107, granulocyte macrophage colony stimulating factor and IgM-enriched immunoglobulin preparations. Biomarkers that guide their use are the expression of the human leukocyte antigen DR on blood monocytes, the absolute lymphocyte count and blood levels of immunoglobulin M. One recently suggested strategy to restore vascular tone is adrecizumab, the use of which is guided by blood levels of bio-adrenomedullin. The use of these precision treatment strategies is still hampered by the need for large-scale randomized controlled trials.

References

[1] Cajander S, Kox M, Scicluna BP, Weigand MA, Mora RA, Flohé SB et al. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. Lancet Respir Med 2024; 12: 305-22. https://doi.org/10.1016/S2213-2600(23)00330-2.

[2] Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709. https://doi.org/10.1056/NEJM200103083441001.

[3] Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S et al. Drotrecogin-alpha (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055-64. https://doi.org/10.1056/NEJMoa1202290.

[4] Gordon AC, Alipanah-Lechner N, Bos LD, Dianti J, Diaz JV, Finfer S et al. From ICU syndromes to ICU subphenotypes: consensus report and recommendations for developing precision medicine in the ICU. Amer J Resp Crit Care Med 2024; 210: 155-66. https://doi.org/10.1164/rccm.202311-2086SO.

[5] Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13: 260-8. https://doi.org/10.1016/S1473-3099(13)70001-X.

[6] Giamarellos-Bourboulis EJ, Antonelli M, Bloos F, Kotsamidi I, Psarrakis C, Dakou K et al. Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality. eBioMedicine 2024; 109: 105414. https://doi.org/10.1016/j.ebiom.2024.105414.

[7] Kyriazopoulou K, Leventogiannis K, Norrby-Teglund A, Dimopoulos G, Pantazi A, Orfanos SE et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med 2017; 15: 172. https://doi.org/10.1186/s12916-017-0930-5.

[8] Anderko RR, Gómez H, Canna SW, Shakoory B, Angus DC, Yealy DM et al. Sepsis with liver dysfunction and coagulopathy predicts an inflammatory pattern of macrophage activation. Intensive Care Med Exp 2022; 10: 6. https://doi.org/10.1186/s40635-022-00433-y.

[9] Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014; 66: 2613-20. https://doi.org/10.1002/art.38690.

[10] Leventogiannis K, Kyriazopoulou E, Antonakos A, Kotsaki A, Tsangaris I, Markopoulou D, et al. Towards personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell Rep Med 2022; 3: 100817. https://doi.org/10.1016/j.xcrm.2022.100817.

[11] Venet F, Tissot S, Debard AL, Faudot C, Crampé A, Pachot A et al. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: correlation with severity and secondary septic shock. Crit Care Med 2007; 35: 1910-7. https://doi.org/10.1097/01.CCM.0000275271.77350.B6.

[12] BD Quantibrite™ Beads; PE fluorescence Quantitation Kit; accessed 09 June 2024; https://www.bdbiosciences.com/content/bdb/paths/generate-tds-document.us.340495.pdf

[13] Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 2016; 4: 259-71. https://doi.org/10.1016/S2213-2600(16)00046-1.

[14] Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med 2017; 5: 816-26. https://doi.org/10.1016/S2213-2600(17)30294-1.

[15] Sweeney TE, Perumal TM, Henao R, Nichols M, Howrylak JA, Choi AM et al. A community approach to mortality prediction in sepsis via gene expression analysis. Nat Commun 2018; 9: 694. https://doi.org/10.1038/s41467-018-03078-2.

[16] Kyriazopoulou E, Hasin-Brumshtein Y, Midic U, Poulakou G, Milionis H, Metallidis S et al. Transitions of blood immune endotypes and improved outcome by anakinra in covid-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial. Crit Care 2024; 28: 73. https://doi.org/10.1186/s13054-024-04852-z.

[17] Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes in sepsis. JAMA 2019; 321: 2003-17. https://doi.org/10.1001/jama.2019.5791.

[18] Bruse N, Kooistra EJ, Jansen A, van Amstel RBE, de Keizer NF, Kennedy JN et al. Clinical sepsis phenotypes in critically ill COVID-19 patients. Crit Care 2022; 26: 244. https://doi.org/10.1186/s13054-022-04118-6.

[19] Kotsaki A, Pickkers P, Bauer M, Calandra T, Lupse M, Wiersinga WJ et al. ImmunoSep (personalised immunotherapy in sepsis) international double-blind, double-dummy, placebo-controlled randomized clinical trial: study protocol. BMJ Open 2022; 12: e067251. https://doi.org/10.1136/bmjopen-2022-067251.

[20] Bidar F, Hamada S, Gossez M, Coudereau R, Lopez J, Cazalis MA et al. Recombinant human interleukin-7 reverses T cell exahustiaon ex vivo in critically ill COVID-19 patients. Ann Intensive Care 2022; 12: 21. https://doi.org/10.1186/s13613-022-00982-1.

[21] Akinosoglou K, Kotsaki A, Gounaridi IM, Christaki E, Metallidis S, Adamis G et al. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial. 2023; 56: 101785. https://doi.org/10.1016/j.eclinm.2022.101785.

[22] Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinnarello CA et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 2016; 44: 275-81. https://doi.org/10.1097/CCM.0000000000001402.

[23] Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen activator receptor: a double-blind, randomized controlled phase 3 trial. Nat Med 2021; 27: 1752-60. https://doi.org/10.1038/s41591-021-01499-z.

[24] Renieris G, Karakike E, Gkavogianni T, Droggiti DE, Stylianakis E, Andriopoulou T et al. IL-1 mediates tissue-specific inflammation and severe respiratory failure in COVID-19. J Inn Immun 2022; 14: 643-56. https://doi.org/10.1159/000524560.

[25] Denning NL, Aziz M, Murao A, Gurien SD, Ochani M, Prince JM et al. Extracellular CRIP as an endogenous TREM-1 ligand to fuel inflammation in sepsis. JCI Insight 2020; 5: e134172. https://doi.org/10.1172/jci.insight.134172.

[26] Boufenzer A, Carrasco K, Jolly L, Brustolin B, Di-Pillo E, Derive M et al. Potentiation of NETs release is novel characteristic of TREM-1 activation and the pharmacological inhibition of TREM-1 could prevent from the deleterious consequences of TREM-1 release in sepsis. Cell Mol Immunol 2021; 18: 452-60. https://doi.org/10.1038/s41423-020-00591-7.

[27] Venet M, Bidar F, Drive M, Delwarde B, Monard C, Hengy B et al. Persistently elevated soluble triggering receptor expressed on myeloid cells 1 and decreased monocytes human leukocytes antigen DR expression are associated with nosocomial infections in septic shock patients. Crit Care Explor 2023; 5: e0869. https://doi.org/10.1097/CCE.0000000000000869.

[28] François B, Witterbole X, Ferrer R, Mira JP, Dugernier T, Gibot S et al. Nangibotide in patients with septic shock: a phase 2a randomized controlled clinical trial. Intensive Care Med 2020; 46: 1425-37. https://doi.org/10.1007/s00134-020-06109-z.

[29] François B, Lambden S, Fivez T, Gibot S, Derive M, Grouin JM et al. Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomized, controlled, phase 2b trial. Lancet Respir Med 2023; 11: 894-904. https://doi.org/10.1016/S2213-2600(23)00158-3.

[30] Bauer M, Weyland A, Marx G, Bllos F, Weber S, Weiler N et al. Efficacy and safety of vilobelimab (IFX-1), a novel monoclonal anti-C5a antibody, in patients with early severe sepsis and septic shock. A randomized, placebo-controlled, double-blind, multicenter, phase IIa study (SCIENS study). Crit Care Explor 2021; 3: e0577. https://doi.org/10.1097/CCE.0000000000000577.

[31] Vlaar APJ, Witzenrath M, van Paassen P, Heunks LMA, Mourvillier B, de Bruin S et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med 2022; 10: 1137-46. https://doi.org/10.1016/S2213-2600(22)00297-1.

[32] Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 2020; 27: 992-1000.e3. https://doi.org/10.1016/j.chom.2020.04.009.

[33] Poscoya A, Parra del Riego A, Cerna-Viacava R, Rocco J, Roman YM, Escobedo AA et al. Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: a systematic review and meta-analysis. PLoS One 2022; 17: e0269368. https://doi.org/10.1371/journal.pone.0269368.

[34] Liu D, Wan B, Yin J, Yu Z, Chen Y, Fan X. Effect of ulinastatin combined with thymosin alpha1 on sepsis: a systematic review and meta-analysis of Chinese and Indian studied. J Crit Care 2017; 39: 285-7. https://doi.org/10.1016/j.jcrc.2017.02.005.

[35] Wilson JK, Zhao Y, Singer M, Spencer J, Shankar-Hari M. Lymphocyte subset expression and serum concentration of PD-1/PD-L1-in sepsis-pilot study. Crit Care 2018; 22: 95. https://doi.org/10.1186/s13054-018-2020-2.

[36] Hian W, Li X, Wen M, Liu X, Wang K, Wang Q et al. Increased percentage of PD-L1+ natural killer cells predicts poor prognosis in sepsis patients: a prospective observational cohort study. Crit Care 2020; 24: 617. https://doi.org/10.1186/s13054-020-03329-z.

[37] Jiang W, Li X, Ding H, Wang K, Liu X, Wang Q et al. PD-1 in Tregs predicts the survival in sepsis patients using sepsis-3 criteria: a prospective, two-stage study. Int Immunopharmacol 2020; 89: 107175. https://doi.org/10.1016/j.intimp.2020.107175.

[38] van den Haak DAC, Otten LS, Koenen HJPM, Smeets RL, Piet B, Pickkers P et al. Evidence-based rationale for low dose nivolumab in critically ill patients with sepsis-induced immunosuppression. Clin Transl Sci 2023; 16: 978-86. https://doi.org/10.1111/cts.13503.

[39] Hotchkiss RS, Colston E, Yende S, Crouser ED, Martin GS, Albertson T et al. Immune checkpoint inhibitions in sepsis: a phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med 2019; 45: 1360-71. https://doi.org/10.1007/s00134-019-05704-z.

[40] Watanabe E, Nishida O, Kakihana Y, Odani M, Okamura T, Harada T et al. Pharmacokinetics, pharmacodynamics, and safety of nivolumab in patients with sepsis-induced immunosuppression: a multicenter, open-label phase 1/2 study. Shock 2020; 53: 686-94. https://doi.org/10.1097/SHK.0000000000001443.

[41] François B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J et al. Interleukin 7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 2018; 3: e98960. https://doi.org/10.1172/jci.insight.98960.

[42] Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Singer M, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med 2018; 44: 438-48. https://doi.org/10.1007/s00134-018-5143-7.

[43] Vacheron CH, Lepape A, Venet F, Monneret G, Gueyffier F, Boutitie F et al. Granulocyte-macrophage colony stimulating factor (GM-CSF) in patients presenting with sepsis-induced immunosuppression: the GIRD randomized controlled trial. J Intensive Care 2023; 78: 154330. https://doi.org/10.1016/j.jcrc.2023.154330.

[44] Prakash V, Arora V, Jindal A, Maiwall R, Kuma SS. Combination of GM CSF and carbapenem is superior to carbapenem monotherapy in difficult-to-treat spontaneous bacterial peritonitis: a randomized controlled trial. Liver Int 2023; 43: 1298-306. https://doi.org/10.1111/liv.15534.

[45] Schrijver DP, Röring RJ, Deckers J, de Dreu A, Toner YC, Prevot G et al. Resolving sepsis-induced immunoparalysis via trained immunity by targeting interleuikin-4 to myeloid cells. Nat Biomed Eng 2023; 7: 1097-112. https://doi.org/10.1038/s41551-023-01050-0.

[46] van Lier D, Kox M, Pickkers P. Promotion of vascular integrity is sepsis through modulation of bioactive adrenomedullin and dipeptyl peptidase 3. J Intern Med 2021; 289: 792-806. https://doi.org/10.1111/joim.13220.

[47] Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman BG, Blet A, et al. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational adrenomedullin and outcome in sepsis and septic shock-1 (AdrenOSS-1) study. Crit Care 2018; 22: 354. https://doi.org/10.1186/s13054-018-2243-2.

[48] Biet A, Deniau B, Santos K, van Lier DPT, Azibani F, Wittebole X et al. Monitoring circulating dipeptyl peptidase 3 (DPP3) predicts involvement of organ failure and survival in sepsis: a prospective observational multinational study. Crit Care 2021; 25: 61. https://doi.org/10.1186/s13054-021-03471-2.

[49] Biet A, de Roquetaillade C, Hartmann O, Struck J, Mebazaa A, Chousterman BG, et al. Added value of serial bioadrenimedullin measurement in addition to lactate for the prognosis of septic patients admitted to the ICU. Crit Care 2020; 24: 69. https://doi.org/10.1186/s13054-020-2794-x.

[50] Deniau B, Blet A, Santos K, Ayar PV, Genest M, Kästorf M et al. Inhibition of circulating dipeptyl-peptidase 3 restores cardiac function in sepsis-induced models in rats: a proof of concept study. Shock 2020; 15: e0238039. https://doi.org/10.1371/journal.pone.0238039.

[51] Geven C, Peters E, Schroedter M, Struck J, Bergmann A, McCook O et al. Effects of the humanized anti-adrenomedullin antibody adrecizumab (HAM8101) on vascular barrier function and survival in rodent models of systemic inflammation and sepsis. Shock 2018; 50: 648-54. https://doi.org/10.1097/SHK.0000000000001102.

[52] Laterre PF, Pickkers P, Marx G, Wittebole X, Meziani F, Dugernier T et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAMB101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial. Intensive Care Med 2021; 47: 1284-94. https://doi.org/10.1007/s00134-021-06537-5.

[53] Biagioni E, Tosi M, Berlot G, Castiglione G, Corona A, De Cristofaro MG et al. Adjunctive IgM-enriched immunoglobulin therapy with a personalised dose based on serum IgM-titres versus standard dose in the treatment of septic shock: a randomised controlled trial (IgM-fat trial). BMJ Open 2021; 11:e036616. https://doi.org/10.1136/bmjopen-2019-036616.

[54] https://clinicaltrials.gov/search?cond=sepsis&term=PALETTENCT06381661.